Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Koichi Ichimura

Showing results (231-240 of 298) with videos related to

Pageof 30
Sort By:
Acta Neuropathologica|May 11, 2013
Differential expression and methylation of brain developmental genes define location-specific subsets of pilocytic astrocytomaSally R Lambert, Hendrik Witt, Volker Hovestadt, et al.
The American Journal of Surgical Pathology|October 12, 2020
CNS Low-grade Diffusely Infiltrative Tumors With INI1 Deficiency, Possessing a High Propensity to Progress to Secondary INI1-deficient Rhabdoid TumorsSumihito Nobusawa, Satoshi Nakata, Yoshiko Nakano, et al.
Cancers|January 11, 2024
KLC1-ROS1 Fusion Exerts Oncogenic Properties of Glioma Cells via Specific Activation of JAK-STAT PathwayTakashi Fujii, Yoshiko Nakano, Daichi Hagita, et al.
Japanese Journal of Clinical Oncology|December 11, 2024
Early progressive disease within 2 years in isocitrate dehydrogenase (IDH)-mutant astrocytoma may indicate radiation necrosisYukie Ozeki, Mai Honda-Kitahara, Shunsuke Yanagisawa, et al.
Cell Cycle (Georgetown, Tex.)|April 4, 2006
Genomic profiling identifies discrete deletions associated with translocations in glioblastoma multiformePaul J Mulholland, Heike Fiegler, Chiara Mazzanti, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|August 27, 2023
KDM2B-Rearranged Soft Tissue Sarcomas Expand the Concept of BCOR-Associated SarcomaToru Motoi, Makoto Hirata, Yoji Kukita, et al.
Acta Neuropathologica|February 12, 2026
Long-term administration of the mutant IDH inhibitor DS-1001b suppresses the growth of IDH1-mutant glioma in vitro and in mouse xenograft models and alters epigenetic profilesKenji Fujimoto, Mai Honda-Kitahara, Naoko Hattori, et al.
Neuro-Oncology Advances|March 9, 2026
<i>BRAF</i>-mutant high-grade glioma with pleomorphic and pseudopapillary features (HPAP): A PLNTY mimic demonstrating tumor progression during longitudinal follow-upYutaro Takayama, Mariko Yaegashi, Kaishi Satomi, et al.
Cancers|December 9, 2020
Enhanced Malignant Phenotypes of Glioblastoma Cells Surviving NPe6-Mediated Photodynamic Therapy are Regulated via ERK1/2 ActivationTatsuya Kobayashi, Makoto Miyazaki, Nobuyoshi Sasaki, et al.
Molecular Cancer Therapeutics|November 16, 2019
A Potent Blood-Brain Barrier-Permeable Mutant IDH1 Inhibitor Suppresses the Growth of Glioblastoma with IDH1 Mutation in a Patient-Derived Orthotopic Xenograft ModelYukino Machida, Makoto Nakagawa, Hironori Matsunaga, et al.
Pageof 30

Showing results (231-240 of 298) with videos related to

Sort By:
Pageof 30
Acta Neuropathologica|May 11, 2013
Differential expression and methylation of brain developmental genes define location-specific subsets of pilocytic astrocytomaSally R Lambert, Hendrik Witt, Volker Hovestadt, et al.
The American Journal of Surgical Pathology|October 12, 2020
CNS Low-grade Diffusely Infiltrative Tumors With INI1 Deficiency, Possessing a High Propensity to Progress to Secondary INI1-deficient Rhabdoid TumorsSumihito Nobusawa, Satoshi Nakata, Yoshiko Nakano, et al.
Cancers|January 11, 2024
KLC1-ROS1 Fusion Exerts Oncogenic Properties of Glioma Cells via Specific Activation of JAK-STAT PathwayTakashi Fujii, Yoshiko Nakano, Daichi Hagita, et al.
Japanese Journal of Clinical Oncology|December 11, 2024
Early progressive disease within 2 years in isocitrate dehydrogenase (IDH)-mutant astrocytoma may indicate radiation necrosisYukie Ozeki, Mai Honda-Kitahara, Shunsuke Yanagisawa, et al.
Cell Cycle (Georgetown, Tex.)|April 4, 2006
Genomic profiling identifies discrete deletions associated with translocations in glioblastoma multiformePaul J Mulholland, Heike Fiegler, Chiara Mazzanti, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|August 27, 2023
KDM2B-Rearranged Soft Tissue Sarcomas Expand the Concept of BCOR-Associated SarcomaToru Motoi, Makoto Hirata, Yoji Kukita, et al.
Acta Neuropathologica|February 12, 2026
Long-term administration of the mutant IDH inhibitor DS-1001b suppresses the growth of IDH1-mutant glioma in vitro and in mouse xenograft models and alters epigenetic profilesKenji Fujimoto, Mai Honda-Kitahara, Naoko Hattori, et al.
Neuro-Oncology Advances|March 9, 2026
<i>BRAF</i>-mutant high-grade glioma with pleomorphic and pseudopapillary features (HPAP): A PLNTY mimic demonstrating tumor progression during longitudinal follow-upYutaro Takayama, Mariko Yaegashi, Kaishi Satomi, et al.
Cancers|December 9, 2020
Enhanced Malignant Phenotypes of Glioblastoma Cells Surviving NPe6-Mediated Photodynamic Therapy are Regulated via ERK1/2 ActivationTatsuya Kobayashi, Makoto Miyazaki, Nobuyoshi Sasaki, et al.
Molecular Cancer Therapeutics|November 16, 2019
A Potent Blood-Brain Barrier-Permeable Mutant IDH1 Inhibitor Suppresses the Growth of Glioblastoma with IDH1 Mutation in a Patient-Derived Orthotopic Xenograft ModelYukino Machida, Makoto Nakagawa, Hironori Matsunaga, et al.
Pageof 30